Pilot Study of Prism EFP NeuroFeedback in Adult ADHD.

A pilot study to preliminarily examine the effects of Prism EFP NeuroFeedback (NF) in adult ADHD. Prism EFP NF is a form of NF specifically designed to target emotional dysregulation (ED) through down regulation of amygdala activity. Prism EFP NF has been shown to improve other disorders with significant ED. Nine participants with adult ADHD received an open trial of Prism EFP NF consisting of fifteen sessions over 8 weeks; all completed at least 5 weeks of treatment with seven completing all 8 weeks. Outcomes were assessed by change in ADHD symptoms from baseline to End of Treatment. About two-third reduction was seen in total DSM ADHD symptom scores (primary outcome measure) with improvement observed in all other clinical measures. No significant adverse events were seen. This preliminary trial found substantial effects of Prism EFP NF on ADHD/ED symptoms and global impairment.

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Lenard A. Adler MD has the following disclosures over the last 3 years: Grant/Research support to NYU Grossman School of Medicine from Shire/Takeda, Otsuka Pharmaceuticals, Corium; Consultant to Supernus Pharmaceuticals, Bracket/Signant, SUNY, Neurocentria, National Football League, Major League Baseball, Otsuka; Royalty payments (as inventor) from NYU Grossman School of Medicine for license of adult ADHD scales and training materials since 2004.; Charles R Marmar MD serves on Advisory Board of Receptor Life Sciences, Otsuka Pharmaceuticals and Roche Products Limited. He has the following disclosures over the last 3 years: National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, Department of Defense- CDMRP US Army Research Office (DARPA), Bank of America Foundation, Brockman Foundation, McCormick Foundation, Home Depot Foundation, New York City Council, New York State Health, Mother Cabrini Foundation, Tilray Pharmaceutical, Ananda Scientific.; Talma Hendler MD PhD is an employee of GrayMatters Health that has patent owned PRISM software provided for the study. Dr. Hendler has stock options as an employee and innovator for GrayMatters.; Yaakov Stern PhD is an employee of GrayMatters Health, which provided the PRISM software for this research.; Oded Kraft is a co-founder and the CEO of GrayMatters Health, which provided the PRISM software for this research.; Deepti Anbarasan MD declared no potential conflicts of interest in the last 3 years.; Dayeon Cho declared no potential conflicts of interest in the last 3 years.; Terry L. Leon declared no potential conflicts of interest in the last 3 years.; Taylor Sardoff declared no potential conflicts of interest in the last 3 years.; Olivia Descorbeth declared no potential conflicts of interest in the last 3 years.